Resolve: ultra-low melatonin dosing suppresses BACE1 without circadian disruption

Bounty tier: $250K dose-response translational study. The challenge tests a non-monotonic dose claim rather than generic melatonin benefit. Falsifiable prediction: in aged APP/PS1 mice and human neuronal cultures, 0.1-0.3 mg human-equivalent dosing will reduce BACE1 mRNA/protein by >=25% and lower Abeta42 generation by >=20% while preserving endogenous circadian amplitude within 10% of baseline. Higher 3-5 mg equivalent dosing should either lose BACE1 advantage or measurably flatten circadian amplitude. If effects are monotonic with dose, the ultra-low replacement hypothesis is falsified.